Is there a Role for Reduced-intensity Haematopoietic Stem Cell Transplantation for Indolent Non-Hodgkin's Lymphoma?

References

• The Non-Hodgkin’s Lymphoma Classification Project (1997) "A clinical evaluation of the International Lymphoma Study Group Classification of non-Hodgkin's lymphoma", Blood 89, 3909–3918.
   PubMed Web of Science ®Google Scholar
• Dimopoulos, M.A., Panayiotidis, P., Moulopoulos, L.A., Sfikakis, P. and Dalakas, M. (2000) "Waldenstrom's macro-globulinemia: clinical features, complications, and manage-ment", J. Clin. Oncol. 18, 214.
   PubMed Web of Science ®Google Scholar
• Johnson, P.W., Rohatiner, A.Z., Whelan, J.S., Price, C.G., Love, S., Lim, J., Matthews, J., Norton, A.J., Amess, J.A. and Lister, TA. (1995) "Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center", J. Clin. Oncol. 13, 140–147.
   PubMed Web of Science ®Google Scholar
• Mijovic, A., Parker, J., Salisbury, J., Pagliuca, A. and Mufti, G.J. (1998) "Autologous blood or bone marrow transplantation for relapsed and partially responding low-grade non-Hodgkin's lymphoma", Cancer Res. Then Control 5, 253–260.
   Web of Science ®Google Scholar
• Apostolidis, J., Foran, J.M., Johnson, P.W., Norton, A., Amess, J., Matthews, J., Bradburn, M., Lister, T.A. and Rohatiner, A.Z. (1999) "Patterns of outcome following recurrence after myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma", J. Clin. Oncol. 17, 216–221.
   PubMed Web of Science ®Google Scholar
• Bierman, P.J., Vose, J.M., Anderson, JR., Bishop, M.R., Kessinger, A. and Armitage, JD. (1997) "High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma", J. Clin. Oncol. 15,445–450.
   PubMed Web of Science ®Google Scholar
• Pappa, V.I., Wilkes, S., Salam, A., Young, B.D., Lister, T.A. and Rohatiner, A.Z. (1998) "Use of the polymerase chain reaction and direct sequencing analysis to detect cells with the t(14;18) in autologous bone marrow from patients with follicular lymphoma, before and after in vitro treatment", Bone Marrow Transplant. 22, 553–558.
   PubMed Web of Science ®Google Scholar
• Brenner, M.K., Rill, D.R., Moen, R.C., Krance, R.A., Mirro, Jr., J., Anderson, W.F. and Ihle, J.N. (1993) "Gene-marking to trace origin of relapse after autologous bone-marrow transplantation", Lancet 341, 85–86.
   PubMed Web of Science ®Google Scholar
• Bachier, C.R., Giles, R.E., Ellerson, D., Hanania, E.G., Garcia-Sanchez, F., Andreeff, M., Cabanillas, F., Champlin, R., Choudhury, R., Berenson, R., Heimfeld, S. and Deisseroth, A.B. (1999) "Hematopoietic retroviral gene marking in patients with follicular non-Hodgkin's lym-phoma", Leuk. Lymphoma 32, 279–288.
   PubMed Web of Science ®Google Scholar
• Freedman, AS., Gribben, J.G., Neuberg, D., Mauch, P. Soiffer, R.J., Anderson, K.C., Pandite, L., Robertson, M.J., Kroon, M., Ritz, J. and Nadler, L.M. (1996) "High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission", Blood 88, 2780–2786.
   PubMed Web of Science ®Google Scholar
• Linassier, C., Fouillard, L., Milpied, N., Tilly, H., Pico, J., Abgrall, J.F., Coiffier, B., Herbrecht, R., Biron, P. and Colombat, P. (1996) "Value of autologous bone marrow transplantation (ABMT) in 42 patients with follicular lymphomas responsive to conventional chemotherapy: a France Autogreffe study", Cancer Detection Prey. 20, 11–19.
   PubMedGoogle Scholar
• Lopez, R., Martino, R., Sureda, A., Nomdedeu, J., Briones, J., Martin-Henao, G., Garcia, J., Brunet, S. and Sierra, J. (1999) "Autologous stem cell transplantation in advanced follicular lymphoma. A single center experience", Haematologica 84, 350–355.
   PubMed Web of Science ®Google Scholar
• Horning, S.J., Negrin, R.S., Hoppe, R.T., Rosenberg, S.A., Chao, N.J., Long, G.D., Brown, B.W. and Blume, K.G. (2001) "High-dose therapy and autologous bone marrow transplan-tation for follicular lymphoma in first complete or partial remission: results of a phase 11 clinical trial", Blood 97, 404–409.
   PubMed Web of Science ®Google Scholar
• Magni, M., Di Nicola, M., Devizzi, L., Matteucci, P., Lombardi, F., Gandola, L., Ravagnani, E, Giardini, R., Dastoli, G., Tarella, C., Pileri, A., Bonadonna, G. and Gianni, A.M. (2000) "Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion", Blood 96, 864–869.
   PubMed Web of Science ®Google Scholar
• Lopez-Guillermo, A., Cabanillas, E, McLaughlin, P., Smith, T., Hagemeister, F., Rodriguez, M.A., Romaguera, J.E., Younes, A., Sarris, A.H., Preti, H.A., Pugh, W. and Lee, US. (1998) "The clinical significance of molecular response in indolent follicular lymphomas", Blood 91, 2955–2960.
   PubMed Web of Science ®Google Scholar
• Freedman, AS., Neuberg, D., Mauch, P., Soiffer, R.J., Anderson, K.C., Fisher, D.C., Schlossman, R., Alyea, E.P., Takvorian, T., Jallow, H., Kuhlman, C., Ritz, J., Nadler, L.M. and Gribben, J.G. (1999) "Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma", Blood 94, 3325–3333.
   PubMed Web of Science ®Google Scholar
• Apostolidis, J., Gupta, R.K., Grenzelias, D., Johnson, P.W., Pappa, V.I., Summers, K.E., Salam, A., Adams, K., Norton, A.J., Amess, J.A., Matthews, J., Bradburn, M., Lister, T.A. and Rohatiner, A.Z. (2000) "High-dose therapy with autologous bone marrow support as consolidation of remission in follicular lymphoma: long-term clinical and molecular follow-up", J. Clin. Oncol. 18, 527–536.
   PubMed Web of Science ®Google Scholar
• Ruvolo, P., Bright, E., Kennedy, M.J., Morris, L., Fischer, A., Vogelsang, G., Jones, R. and Hess, A. (1995) "Cyclosporine-induced autologous graft versus host disease: assessment of cytolytic effector mechanisms and the V beta T-cell receptor repertoire", Transplant. Proc. 27, 1363–1365.
   PubMed Web of Science ®Google Scholar
• Traweek, ST., Slovak, M.L., Nademanee, A.P., Brynes, R.K., Niland, J.C. and Forman, S.J. (1996) "Myelodysplasia and acute myeloid leukemia occurring after autologous bone marrow transplantation for lymphoma", Leuk. Lymphoma 20, 365–372.
   PubMed Web of Science ®Google Scholar
• Wilson, CS., Traweek, ST., Slovak, M.L., Niland, J.C., Forman, S.J. and Brynes, R.K. (1997) "Myelodysplastic syndrome occurring after autologous bone marrow trans-plantation for lymphoma. Morphologic features", Am. J. Clin. Pathol. 108, 369–377.
   PubMed Web of Science ®Google Scholar
• Stone, R.M., Neuberg, D., Soiffer, R., Takvorian, T., Whelan, M., Rabinowe, S.N., Aster, J.C., Leavitt, P., Mauch, P. and Freedman, AS. (1994) "Myelodysplastic syndrome as a late complication following autologous bone marrow transplan-tation for non-Hodgkin's lymphoma", J. Clin. Oncol. 12, 2535–2542.
   PubMed Web of Science ®Google Scholar
• Friedberg, J.W., Neuberg, D., Stone, R.M., Alyea, E., Jallow, H., LaCasce, A., Mauch, PM., Gribben, J.G., Ritz, J., Nadler, L.M., Soiffer, R.J. and Freedman, AS. (1999) "Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lym-phoma", J. Clin. Oncol. 17, 3128–3135.
   PubMed Web of Science ®Google Scholar
• Jones, R.J., Ambinder, R.F., Piantadosi, S. and Santos, G.W. (1991) "Evidence of a graft-versus-lymphoma effect associ-ated with allogeneic bone marrow transplantation", Blood 77, 649–653.
   PubMed Web of Science ®Google Scholar
• Verdonck, L.F., Dekker, A.W., Lokhorst, H.M., Petersen, E.J. and Nieuwenhuis, H.K. (1997) "Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin's lymphoma", Blood 90, 4201–4205.
   PubMed Web of Science ®Google Scholar
• Stein, R.S., Greer, J.P., Goodman, S., Kallianpur, A., Ahmed, M.S. and Wolff, S.N. (1999) "High-dose therapy with autologous or allogeneic transplantation as salvage therapy for small cleaved cell lymphoma of follicular center cell origin", Bone Marrow Transplant. 23, 227–233.
   PubMed Web of Science ®Google Scholar
• van Besien, K.W., Khouri, IF, Giralt, S.A., McCarthy, P., Mehra, R., Andersson, B.S., Przepiorka, D., Gajewski, J.L., Bellare, N., Nath, R., et al. (1995) "Allogeneic bone marrow transplantation for refractory and recurrent low-grade lymphoma: the case for aggressive management", J. Clin. Oncol. 13, 1096–1102.
   PubMed Web of Science ®Google Scholar
• van Besien, K., Sobocinski, K.A., Rowlings, P.A., Murphy, S.C., Armitage, JD., Bishop, MR., Chaekal, O.K., Gale, R.P., Klein, J.P., Lazarus, H.M., McCarthy, Jr., Pi., Raemaekers, J.M., Reiffers, J., Phillips, G.L., Schattenberg, A.V., Verdonck, L.F., Vose, J.M. and Horowitz, UM. (1998) "Allogeneic bone marrow transplantation for low-grade lymphoma", Blood 92, 1832–1836.
   PubMed Web of Science ®Google Scholar
• Toze, CL., Shepherd, J.D., Connors, J.M., Voss, N.J., Gascoyne, RD., Hogge, D.E., Klingemarm, HG., Nantel, S.H., Nevill, T.J., Phillips, G.L., Reece, D.E., Sutherland, H.J. and Barnett, M.J. (2000) "Allogeneic bone marrow transplan-tation for low-grade lymphoma and chronic lymphocytic leukemia", Bone Marrow Transplant. 25, 605–612.
   PubMed Web of Science ®Google Scholar
• Forrest, Di., Thompson, K., Nevill, T.J., Couban, S. and Fernandez, L.A. (2002) "Allogeneic hematopoietic stem cell transplantation for progressive follicular lymphoma", Bone Marrow Transplant. 29, 973–978.
   PubMed Web of Science ®Google Scholar
• Mandigers, CM., Raemaekers, J.M., Schattenberg, A.V., Roovers, E.A., Bogman, M.J., van der Maazen, R.W., De Pauw, B.E. and De Witte, T. (1998) "Allogeneic bone marrow transplantation with T-cell-depleted marrow grafts for patients with poor-risk relapsed low-grade non-Hodgkin's lymphoma", Br. J. Haematol. 100, 198–206.
   PubMed Web of Science ®Google Scholar
• Colombat, P., Salles, G., Brousse, N., Eftekhari, P., Soubeyran, P., Delwail, V., Deconinck, E., Haioun, C., Foussard, C., Sebban, C., Stamatoullas, A., Milpied, N., Boue, F., Taillan, B., Lederlin, P., Najman, A., Thieblemont, C., Montestruc, F., Mathieu-Boue, A., Benzohra, A. and Solal-Celigny, P. (2001) "Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation", Blood 97, 101–106.
   PubMed Web of Science ®Google Scholar
• Feuring-Buske, M., Kneba, M., Unterhalt, M., Engert, A., Gramatzki, M., Hiller, E., Trumper, L., Brugger, W., Ostermann, H., Atzpodien, J., Hallek, M., Aulitzky, E. and Hiddemann, W. (2000) "IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group", Ann. Hematol. 79, 493–500.
   PubMed Web of Science ®Google Scholar
• Hainsworth, J.D., Burris, 3rd, HA., Morrissey, L.H., Litchy, S., Scullin, Jr., D.C., Bearden, 3rd, J.D., Richards, P. and Greco, F.A. (2000) "Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma", Blood 95, 3052–3056.
   PubMed Web of Science ®Google Scholar
• Kolb, H.J., Schattenberg, A., Goldman, J.M., Hertenstein, B., Jacobsen, N., Arcese, W., Ljungman, P., Ferrant, A., Verdonck, L. and Niederwieser, D. (1995) "Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia", Blood 86, 2041–2050.
   PubMed Web of Science ®Google Scholar
• Kolb, H.J. (1998) "Donor leukocyte transfusions for treatment of leukemic relapse after bone marrow transplantation. EBMT Immunology and Chronic Leukemia Working Parties", Vox Sanguinis 74, 321–329.
   PubMed Web of Science ®Google Scholar
• Rondon, G., Giralt, S., Huh, Y, Khouri, I., Andersson, B., Andreeff, M. and Champlin, R. (1996) "Graft-versus-leukemia effect after allogeneic bone marrow transplantation for chronic lymphocytic leukemia", Bone Marrow Transplant. 18, 669–672.
   PubMed Web of Science ®Google Scholar
• Dann, E.J., Daugherty, C.K. and Larson, R.A. (1997) "Allogeneic bone marrow transplantation for relapsed and refractory Hodgkin's disease and non-Hodgkin's lym-phoma", Bone Marrow Transplant. 20, 369–374.
   PubMed Web of Science ®Google Scholar
• Khouri, IF, Keating, M., Korbling, M., Przepiorka, D., Anderlini, R, O'Brien, S., Giralt, S., Ippoliti, C., von Wolff, B., Gajewski, J., Donato, M., Claxton, D., Ueno, N., Andersson, B., Gee, A. and Champlin, R. (1998) "Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies", J. Clin. Oncol. 16, 2817–2824.
   PubMed Web of Science ®Google Scholar
• Slavin, S., Nagler, A., Naparstek, E., Kapelushnik, Y., Aker, M., Cividalli, G., Varadi, G., Kirschbaum, M., Ackerstein, A., Samuel, S., Amar, A., Brautbar, C., Ben-Tal, O., Eldor, A. and Or, R. (1998) "Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases", Blood 91, 756–763.
   PubMed Web of Science ®Google Scholar
• Freedman, AS., Gribben, J.G. and Nadler, L.M. (1998) "High dose therapy and autologous stem cell transplantation in follicular non-Hodgkin's lymphoma", Leuk. Lymphoma 28, 219–230.
   PubMed Web of Science ®Google Scholar
• Nagler, A., Slavin, S., Varadi, G., Naparstek, E., Samuel, S. and Or, R. (2000) "Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma", Bone Marrow Transplant. 25, 1021–1028.
   PubMed Web of Science ®Google Scholar
• Khouri, IF, Saliba, R.M., Giralt, S.A., Lee, MS., Okoroji, G.J., Hagemeister, F.B., Korbling, M., Younes, A., Ippoliti, C., Gajewski, J.L., McLaughlin, R, Anderlini, R, Donato, M.L., Cabanillas, F.F. and Champlin, R.E. (2001) "Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality", Blood 98, 3595–3599.
   PubMed Web of Science ®Google Scholar
• Dreger, R, Glass, B., Seyfarth, B., Humpe, A., Claviez, A., von Neuhoff, N., Suttorp, M., Schoch, R. and Schmitz, N. (2000) "Reduced-intensity allogeneic stem cell transplantation as salvage treatment for patients with indolent lymphoma or CLL after failure of autologous SCT", Bone Marrow Transplant. 26, 1361–1362.
   PubMed Web of Science ®Google Scholar
• Martino, R., Caballero, M.D., Canals, C., Simon, J.A., Solano, C., Urbano-Ispizua, A., Bargay, J., Rayon, C., Leon, A., Sarra, J., Odriozola, J., Conde, J.G., Sierra, J. and San Miguel, J. (2001) "Allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning: results of a prospective multicentre study", Br. J. Haematol. 115, 653–659.
   PubMed Web of Science ®Google Scholar
• Corradini, R, Tarella, C., Olivieri, A., Gianni, AM., Voena, C., Zallio, E, Ladetto, M., Falda, M., Lucesole, M., Dodero, A., Ciceri, F., Benedetti, E, Rambaldi, A., Sajeva, MR., Tresoldi, M., Pileri, A., Bordignon, C. and Bregni, M. (2002) "Reduced-intensity conditioning followed by allografting of hemato-poietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies", Blood 99, 75–82.
   PubMed Web of Science ®Google Scholar
• Mohty, M., Fegueux, N., Exbrayat, C., Lu, Z.Y., Legouffe, E., Quittet, P., Lopez-Martinez, E., Latry, R, Avinens, O., Hertog, C., Klein, B., Eliaou, J.F. and Rossi, J.F. (2001) "Reduced intensity conditioning: enhanced graft-versus-tumor effect following dose-reduced conditioning and allogeneic trans-plantation for refractory lymphoid malignancies after high-dose therapy", Bone Marrow Transplant. 28, 335–339.
   PubMed Web of Science ®Google Scholar
• Bastion, Y, Brice, R, Haioun, C., Sonet, A., Salles, G., Marolleau, J.P., Espinouse, D., Reyes, F., Gisselbrecht, C. and Coiffier, B. (1995) "Intensive therapy with peripheral blood progenitor cell transplantation in 60 patients with poor-prognosis follicular lymphoma", Blood 86, 3257–3262.
   PubMed Web of Science ®Google Scholar
• van Besien, K., Demuynck, H., Lemaistre, C.F., Bogaerts, M.A. and Champlin, R. (1995) "High-dose melphalan allows durable engraftment of allogeneic bone marrow", Bone Marrow Transplant. 15, 321–323.
   PubMed Web of Science ®Google Scholar
• Przepiorka, D., van Besien, K., Khouri, I., Hagemeister, F., Samuels, B., Folloder, J., Ueno, N.T., Molldrem, J., Mehra, R., Korbling, M., Giralt, S., Gajewski, J., Donato, M., Cleary, K., Claxton, D., Braunschweig, I., Andersson, B., Anderlini, P. and Champlin, R. (1999) "Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma", Ann. Oncol. 10, 527–532.
   PubMed Web of Science ®Google Scholar
• Cull, G.M., Haynes, A.P., Byrne, J.L., Carter, G.I., Miflin, G., Rebello, R, Hale, G., Waldmann, H. and Russell, N.H. (2000) "Preliminary experience of allogeneic stem cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH conditioning: an effective regimen with low procedure-related toxicity", Br. J. Haematol. 108, 754–760.
   PubMed Web of Science ®Google Scholar
• Hale, G., Zhang, M.J., Bunjes, D., Prentice, HG., Spence, D., Horowitz, UM., Barrett, A.J. and Waldmann, H. (1998) "Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection", Blood 92, 4581–4590.
   PubMed Web of Science ®Google Scholar
• Hale, G., Jacobs, P., Wood, L., Fibbe, W.E., Barge, R., Novitzky, N., Toit, C., Abrahams, L., Thomas, V, Bunjes, D., Duncker, C., Wiesneth, M., Selleslag, D., Hidajat, M., Starobinski, M., Bird, P. and Waldmann, H. (2000) "CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells", Bone Marrow Transplant. 26, 69–76.
   PubMed Web of Science ®Google Scholar
• Buggins, A.G.S., Mufti, G.J., Salisbury, J., Codd, J., Westwood, N., Arno, M., Fishlock, K., Pagliuca, A. and Devereux, S. (2002) "Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumab", Blood 100, 1715–1720.
   PubMed Web of Science ®Google Scholar
• Khouri, I., Saliba, R. and Giralt, S. (2000) "Allogeneic hematopoietic transplantation for indolent lymphomas: improved outcome with non-myeloablative versus high dose chemotherapy (HDCT) regimens", Blood 96, 199a, Abstract.
   Web of Science ®Google Scholar
• Chakraverty, R., Peggs, K., Chopra, R., Milligan, D.W., Kottaridis, PD., Verfuerth, S., Geary, J., Thuraisundaram, D., Branson, K., Chakrabarti, S., Mahendra, R, Craddock, C., Parker, A., Hunter, A., Hale, G., Waldmann, H., Williams, CD., Yong, K., Linch, D.C., Goldstone, A.H. and Mackinnon, S. (2002) "Limiting transplantation-related mortality follow-ing unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen", Blood 99, 1071–1078.
   PubMed Web of Science ®Google Scholar
• Milpied, N., Coste-Burel, M., Accard, F., Moreau, A., Moreau, R, Garand, R. and Harousseau, J.L. (1999) "Epstein—Barr virus-associated B cell lymphoproliferative disease after non-myeloablative allogeneic stem cell transplantation", Bone Marrow Transplant. 23, 629–630.
   PubMed Web of Science ®Google Scholar
• Ho, A.Y., Adams, S., Shaikh, H., Pagliuca, A., Devereux, S. and Mufti, G.J. (2002) "Fatal donor-derived Epstein—Barr virus-associated post-transplant lymphoproliferative dis-order following reduced intensity volunteer-unrelated bone marrow transplant for myelodysplastic syndrome", Bone Marrow Transplant. 29, 867–869.
   PubMed Web of Science ®Google Scholar
• Curtis, RE., Travis, L.B., Rowlings, RA., Socie, G., Kingma, D.W., Banks, P.M., Jaffe, ES., Sale, G.E., Horowitz, UM., Witherspoon, R.P., Shriner, D.A., Weisdorf, D.J., Kolb, H.J., Sullivan, KM., Sobocinski, K.A., Gale, R.P., Hoover, R.N., Fraumeni, Jr., J.F. and Deeg, H.J. (1999) "Risk of lymphopro-liferative disorders after bone marrow transplantation: a multi-institutional study", Blood 94, 2208–2216.
   PubMed Web of Science ®Google Scholar
• Hale, G. and Waldmann, H. (1998) "Risks of developing Epstein—Barr virus-related lymphoproliferative disorders after T-cell-depleted marrow transplants. CAMPATH Users", Blood 91, 3079–3083.
   PubMed Web of Science ®Google Scholar
• Steven, N., Chakrabarti, S. and Holder, K. (2000) "Reconstitu-tion of Epstein—Barr virus-specific T-cell responses in recipients of peripheral blood stem cell allografts treated with CAMPATH-1H", Blood 96, 376a, Abstract.
   Web of Science ®Google Scholar
• Chakrabarti, S., Mackinnon, S., Chopra, R., Kottaridis, P.D., Peggs, K., O'Gorman, E, Chakraverty, R., Marshall, T., Osman, H., Mahendra, P., Craddock, C., Waldmann, H., Hale, G., Fegan, C.D., Yong, K., Goldstone, A.H., Linch, D.C. and Milligan, D.W. (2002) "High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune recon-stitution", Blood 99, 4357–4363.
   PubMed Web of Science ®Google Scholar
• Chakraverty, R., Robinson, S., Peggs, K., Kottaridis, P.D., Watts, M.J., Ings, S.J., Hale, G., Waldmann, H., Linch, D.C., Goldstone, A.H. and Mackinnon, S. (2001) "Excessive T cell depletion of peripheral blood stem cells has an adverse effect upon outcome following allogeneic stem cell transplan-tation", Bone Marrow Transplant. 28, 827–834.
   PubMed Web of Science ®Google Scholar
• Carella, A.M., Cavahere, M., Lerma, E., Ferrara, R., Tedeschi, L., Rommel, A., Vinci, M., Pinotti, G., Lambelet, E, Loin, C., Verdiani, S., De Stefano, E, Valbonesi, M. and Corsetti, M.T. (2000) "Autografting followed by nonmyeloablative immu-nosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lym-phoma", J. Clin. Oncol. 18, 3918–3924.
   PubMed Web of Science ®Google Scholar
• Milojkovic, D., Mijovic, A., Taylor, C.G., Mufti, G.J. and Pagliuca, A. (2000) "Rituximab salvage following relapse after allogeneic bone marrow transplantation for non-Hodgkin's lymphoma", Br. J. Haematol. 110, 1013–1014.
   PubMed Web of Science ®Google Scholar
• Ho, A.Y.L., Devereux, S., Mufti, G. and Pagliuca, A. (2001) "Reduced-intensity Rituximab-BEAM-CAMPATH allogeneic transplantation for indolent non-Hodgkin's lymphoma", Blood 98, 188a, Abstract.
   Web of Science ®Google Scholar